Rationale and Design of the Phase 2b Clinical Trials to Study the Effects of the Partial Adenosine A1-Receptor Agonist Neladenoson Bialanate in Patients With Chronic Heart Failure With Reduced (PANTHEON) and Preserved (PANACHE) Ejection Fraction
European Journal of Heart Failure - United States
doi 10.1002/ejhf.1295
Full Text
Open PDFAbstract
Available in full text
Date
September 17, 2018
Authors
Publisher
Wiley